Allurion restates Q3, posts GAAP profit from fair‑value gains amid revenue collapse and NYSE risk

Snapshot - Allurion Technologies, Inc. (NYSE: ALUR)

Allurion just filed an amended Q3 2024 10‑Q/A: it restated Q3 (and other prior) results after finding booking errors tied to internal control weaknesses, completed a 1‑for‑25 reverse split, drove a large fair‑value swing that produced a GAAP Q3 profit, and faces regulatory, liquidity and listing risks.

Key facts & figures (from the restated financials, dollars in thousands unless noted)

- Cash & cash equivalents (9/30/2024): $28,654

- Cash + restricted cash (statement of cash flows): $29,045

- Total assets (9/30/2024): $50,699

- Total liabilities (9/30/2024): $114,510

- Stockholders' deficit (9/30/2024): $(64,790)

- Accumulated deficit (9/30/2024): $(212,599)

- Revenue: Q3 2024: $5,367 vs Q3 2023: $18,200; 9M 2024: $26,519 vs 9M 2023: $45,232

- Gross profit: Q3 2024: $3,111 (down sharply y/y)

- Operating loss: Q3 2024: $(12,341); 9M 2024: $(33,083)

- Other income (fair‑value / derivatives / one‑offs): Q3 2024: $21,146 - drove GAAP net income

- Net income (restated): Q3 2024: $8,736 (vs loss prior year); 9M 2024: $2,410

- Major balance sheet items: Revenue Interest Financing liability $38,500; Convertible notes payable (carrying) $36,090; Warrant liabilities $7,381; Earn‑out liabilities $1,850

- Cash used in operations (9M 2024): $(29,026)

- Shares outstanding (as disclosed): various post‑split counts - see filing for detailed share tables

What's happening inside the company - the essentials

- Restatement & controls: Management discovered an error caused by insufficient public‑company / technical accounting staffing and control gaps that led to incorrect booking of fair‑value and OCI items since Q4 2023. The company restated prior interim and annual periods and identified material weaknesses in internal control over financial reporting.

- Fair‑value volatility: Large recurring mark‑to‑market swings (warrants, convertible debt, revenue‑interest financing, earn‑outs) dominate "Other income (expense)" and produced a GAAP Q3 profit despite an operating loss. Those non‑cash items create earnings volatility quarter to quarter.

- Financing and capital structure: The company refinanced debt (issued $48M RTW convertible notes in April 2024), completed a public offering and a private placement in July 2024 (warrants and Series A preferred), repaid a prior term loan (with an $8.7M extinguishment loss) and carries revenue‑interest obligations tied to RTW financing.

- Regulatory & commercial pressure: ANSM (France) suspended sales of the Allurion Balloon in Aug 2024; Allurion withdrew the device from France and submitted a remediation plan. Revenue has fallen substantially (Q3 revenue down ~71% y/y) as distributors reduced orders and France returns impacted sales.

- NYSE risk: The company received NYSE notices for low share price and low market capitalization (below $1 average and below $50M MC threshold), and has submitted a plan to regain compliance - delisting risk exists if cure fails.

Income statement - positives

- GAAP improvement in Q3:** Net income of $8,736 (restated) for Q3 2024 driven by $21,146 of other income (mainly fair‑value gains). This produced positive EPS for the quarter (basic $3.41/share).

- Cost discipline:** Operating expenses materially declined y/y (sales & marketing, R&D and G&A all down) - management cut marketing, restructured sales spend and reduced headcount/clinical spend.

Income statement - negatives / risks

- Revenue collapse:** Q3 revenue = $5,367 vs $18,200 prior year - large drop in sales volume and geographic impacts (France suspension + distributor destocking).

- Operating losses persist:** Operating loss Q3 $(12,341) - the GAAP profit is driven by non‑operating fair‑value items, not underlying operations.

- Earnings quality / volatility:** Large fair‑value swings (warrants, convertible debt, RIF/PIPE option, earn‑outs) pivot reported profitability - results are sensitive to assumptions and stock price.

- Internal control & restatement:** Material weaknesses and a restatement erode investor trust and complicate forecasts; bookkeeping errors affected net income, OCI and accumulated deficit balances.

Bottom line / immediate takeaways

- The business is under stress: revenues are falling, operating losses continue, cash burn remains significant and balance sheet is levered with hybrid financing (revenue share + convertible notes + warrants).

- Reported Q3 profitability is driven by non‑cash fair‑value gains - not by operational recovery. Watch revenue trends, cash runway and whether France remediation succeeds.

- Key monitors for investors: (1) monthly revenue / order cadence and distributor inventory levels, (2) ANSM remediation progress and reinstatement in France, (3) cash balance and covenant compliance under RTW notes/RIF, (4) progress remediating internal control weaknesses and the quality of future filings, and (5) NYSE compliance status.

If you want, I can produce a one‑page quick financial dashboard (P&L & balance sheet highlights) and a 30/60/90‑day watchlist of operational and regulatory milestones to follow.